Skip to main content

Table 2 Immunosuppressive regimen according to follow-up time in kidney transplant patients, (n = 450)

From: Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis

  3 months N (%) 6 months N (%) 12 months N (%) 18 months N (%)
TAC/MPA/MP 212 (47.1) 217 (48.2) 215 (47.8) 210 (46.7)
CsA/MPA/MP 145 (32.2) 144 (32.0) 131 (29.1) 114 (25.3)
TAC/mTORi/MP 72 (16) 60 (13.3) 53 (11.8) 50 (11.1)
CsA/mTORi/MP 1 (0.2) 1 (0.2) 1 (0,2) 0 (0)
MPA/mTORi/MP 16 (3.6) 15 (3.3) 24 (5,3) 24 (5,3)
Double immunosuppressive regimen 2 (0.4) 3 (0.7) 15 (3,3) 36 (8.0)
None/unknown 2 (0.4) 10 (2.2) 11 (2.4) 16 (3.6)
  1. TAC: tacrolimus; MPA: mycophenolatemofetil or mycophenolate sodium; MP: methylprednisolone; CsA: cyclosporine; mTORi: rapammune or everolimus